LifeVantage reports Q3 EPS 11c, consensus 16c

Reports Q3 revenue $43.72M, consensus $47.77M. “Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 System were only partially offset by the addition of LoveBiome,” said Michael Beindorff, Interim CEO of LifeVantage (LFVN). “Despite top-line headwinds, we remained focused on managing expenses and allocating capital, enabling us to continue repurchasing shares while maintaining a strong balance sheet and cash position. That said, we are not satisfied with our performance and are laser focused on making the changes necessary to improve results going forward. With our science-backed approach to nutrigenomics, diversified product portfolio, passionate consultant community, and strong financial foundation, LifeVantage is in a compelling position in the rapidly expanding health and wellness market with significant growth potential ahead, and we intend to realize that potential.”